SMN-inducing compounds for the treatment of spinal muscular atrophy.
about
Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophySmall molecule suppressors of Drosophila kinesin deficiency rescue motor axon development in a zebrafish model of spinal muscular atrophyThe DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models.Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation.Defining the therapeutic window in a severe animal model of spinal muscular atrophyAssays for the identification and prioritization of drug candidates for spinal muscular atrophyEnhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compoundsA cell system for phenotypic screening of modifiers of SMN2 gene expression and function.SAM68 is a physiological regulator of SMN2 splicing in spinal muscular atrophy.Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?Pig models of neurodegenerative disorders: Utilization in cell replacement-based preclinical safety and efficacy studies.Spinal muscular atrophy--recent therapeutic advances for an old challenge.Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models.Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy.
P2860
Q28279022-883DBA7A-174D-4FFE-8E66-B66FFE7C5706Q28536678-736ECCCF-073D-4BC7-B1F3-9643FE31BC20Q30546337-BFFC5F23-EC39-4F14-8858-6D03998A3D1CQ30569780-CAE7F9BB-2C93-427A-ADFB-DFE805B24CB9Q33991731-96FC1E0E-5222-42DD-AA21-B8A3D70C16ECQ34082155-6DDA1578-F304-49AA-86CD-AF7ED9B45D2BQ34760255-85D0B41B-85BE-4AF6-A00D-0F5D515A0E29Q34964785-2DACB8F8-015E-4073-8ED3-D507DCA5E97EQ36149380-3D1BC4F7-C043-4E0E-8BB0-549211A42409Q38123249-F86BAFB1-B6EC-465A-9B75-3B02BD66B97AQ38194510-D10A88DE-AB72-48F3-BCC0-B650A47A5484Q38489298-9B1A0BCB-FBF3-4997-89EC-58D84AD98BE4Q42218490-03609A3F-D2A5-4698-9075-34E0F4A24F0EQ48144714-DF9F536E-111D-418B-B5F0-9E4BA61CDBFC
P2860
SMN-inducing compounds for the treatment of spinal muscular atrophy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@ast
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@en
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@nl
type
label
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@ast
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@en
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@nl
prefLabel
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@ast
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@en
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@nl
P2860
P356
P1476
SMN-inducing compounds for the treatment of spinal muscular atrophy.
@en
P2093
Christian L Lorson
Monique A Lorson
P2860
P304
P356
10.4155/FMC.12.131
P577
2012-10-01T00:00:00Z